What's happening
Indiana Governor Mike Braun and pharmaceutical giant Eli Lilly signed a letter of intent on April 17, 2026, to develop nuclear power projects including small modular reactors for Indiana's electrical grid. The partnership follows the passage of pro-nuclear Senate Bill 424 and aims to provide reliable, emissions-free power to meet massive electricity demands from AI data centers. "Advanced nuclear technology represents the kind of bold, clean energy solution our state needs to power the next generation of innovation, and it directly supports Lilly's own commitment to reduce our environmental footprint," said Dave Ricks, Chair and CEO of Eli Lilly.
The nuclear initiative supports major technology investments in Indiana's LEAP District, where Eli Lilly is investing $13 billion in a research and medicine-manufacturing facility while Meta is building a $10 billion, 1,500-acre data center campus. Governor Braun emphasized the economic benefits, stating "Indiana is leading on nuclear power, because more energy means lower energy prices for Hoosier families."
Why it matters for markets
Eli Lilly's nuclear partnership represents a $829.71 billion market cap pharmaceutical company joining the nuclear revival driven by AI power demands. With the company generating $65.18 billion in revenue and trading at $927.03 per share, Lilly's $13 billion LEAP District investment demonstrates how major corporations are securing long-term energy infrastructure for data-intensive operations. The partnership positions Lilly alongside technology giants in addressing the massive electricity requirements of AI data centers.
The timing coincides with broader nuclear sector momentum, as First American Nuclear submitted its regulatory engagement plan for the EAGL-1 reactor to the NRC on April 15. Meta's concurrent $10 billion data center investment in the same district highlights the scale of energy infrastructure needed to support AI operations. For Lilly, which employs 50,000 people and trades at a P/E ratio of 40.4, securing reliable power sources supports its manufacturing operations and research facilities in a state positioning itself as a nuclear energy leader.
Sectors and assets to watch
Healthcare companies with significant manufacturing and research operations may follow Lilly's approach to securing dedicated power infrastructure, particularly those investing heavily in AI-driven drug discovery. The nuclear sector benefits from pharmaceutical industry adoption, adding to demand from technology companies already pursuing small modular reactor partnerships. Utility companies operating in states with pro-nuclear legislation like Indiana's Senate Bill 424 could see increased development opportunities.
Energy infrastructure companies specializing in SMR technology and nuclear project development stand to benefit from corporate partnerships beyond the traditional technology sector. The convergence of pharmaceutical manufacturing, AI data centers, and nuclear power in Indiana's LEAP District creates a model that other states and corporations may replicate.
What to watch next
Monitor regulatory filings related to Indiana's nuclear projects and any additional corporate partnerships Governor Braun announces following the Lilly agreement. Track First American Nuclear's EAGL-1 reactor progress through NRC review processes and whether other pharmaceutical companies announce similar nuclear partnerships. Watch for updates on the LEAP District development timeline and how the $13 billion Lilly facility and $10 billion Meta data center coordinate their power requirements with the planned nuclear infrastructure.